Dr Graham Boulnois has been a director of Oxagen since 2005. He is a partner in SVLS where he has been since 2001, is a Director of Alantos and Deputy Director of Gyros AB and Affibody AB.

Before joining SVLS, Graham was Senior Vice President in the R&D function at Aventis Pharma where he had global responsibility for Lead Generation. Prior to joining Aventis, Graham spent a number of years at Zeneca Pharmaceuticals as Senior Vice President, Discovery Research and then with AstraZeneca Pharmaceuticals as Global Vice President, Enabling Science and Technology. Before joining the pharmaceutical industry, he was Professor of Microbiology, Chairman of Biological Sciences and Pro-Dean of the Science Faculty at Leicester University.

Graham has a BSc in Biological Science and a PhD in Molecular Biology from the University of Leicester.